Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target mRNAs with partial complementarity to the DLST siRNA guide strand represent a diverse group of unintended genetic transcripts that are downregulated during RNA interference (RNAi) experiments targeting Dihydrolipoamide S-Succinyltransferase (DLST). This phenomenon occurs when the siRNA guide strand recognizes and binds to mRNAs that share sequence similarity, particularly in the 3' untranslated region (UTR), a process often driven by the 6-8 nucleotide 'seed' sequence [1]. DLST itself is a vital enzyme in the mitochondrial tricarboxylic acid (TCA) cycle, and its silencing is frequently investigated in oncology and metabolic research [2]. However, the silencing of these off-target mRNAs can induce cellular phenotypes, such as reduced viability or altered metabolism, that are independent of the intended DLST knockdown [3]. These interactions represent a major challenge in the development of siRNA-based therapeutics, as they can lead to unforeseen toxicities and complicate the interpretation of biological data [4]. Consequently, these mRNAs are not therapeutic targets but are critical factors to be minimized through chemical modification or optimized sequence design in drug development.
The DLST siRNA guide strand incorporates into the RNA-induced silencing complex (RISC) and binds to off-target mRNAs via partial complementarity, primarily through the seed region (nucleotides 2-8), leading to mRNA cleavage or translational inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target mRNAs with partial complementarity to the DLST siRNA guide strand.